InvestSMART

Proteomics International Laboratories Ltd (ASX: PIQ) - Announcements

- Current share price for PIQ : $0.155

ASX company news and announcements for Proteomics International Laboratories Ltd (PIQ) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Proteomics International Laboratories Ltd (PIQ) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Proteomics International Laboratories Ltd (PIQ), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Proteomics International Laboratories Ltd (PIQ)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$26 PromarkerD test kit production deal signed 11 Nov 2016 9:27AM $0.250 $0.155 fallen by 38%
$26 Proteomics wins WA Exporter of the Year 31 Oct 2016 9:11AM $0.300 $0.155 fallen by 48.33%
$26 Proteomics presents at Australia Biotech Invest 2016 26 Oct 2016 10:01AM $0.290 $0.155 fallen by 46.55%
$26 Appendix 4C - September 2016 Quarterly Report 25 Oct 2016 10:14AM $0.290 $0.155 fallen by 46.55%
$26 Proteomics targets gastro-causing parasite 20 Oct 2016 9:32AM $0.290 $0.155 fallen by 46.55%
$26 Notice of Annual General Meeting/Proxy Form 19 Oct 2016 8:20AM $0.290 $0.155 fallen by 46.55%
$26 Initial Director's Interest Notice 18 Oct 2016 12:48AM $0.270 $0.155 fallen by 42.59%
$26 Proteomics appoints new director 14 Oct 2016 10:38AM $0.260 $0.155 fallen by 40.38%
$26 Research Report 4 Oct 2016 9:49AM $0.245 $0.155 fallen by 36.73%
$26 Proteomics International receives FY16 R&D Tax Incentive 21 Sep 2016 12:15AM $0.235 $0.155 fallen by 34.04%
$26 Proteomics investigates biomarkers for mesothelioma 6 Sep 2016 10:39AM $0.260 $0.155 fallen by 40.38%
$26 Corporate Governance Statement and Appendix 4G 26 Aug 2016 5:29PM $0.250 $0.155 fallen by 38%
$26 Annual Report to shareholders 26 Aug 2016 5:29PM $0.250 $0.155 fallen by 38%
$26 Preliminary Final Report 26 Aug 2016 4:52PM $0.250 $0.155 fallen by 38%
$26 Proteomics expands diagnostics portfolio to endometriosis 24 Aug 2016 10:01AM $0.240 $0.155 fallen by 35.42%
$26 Proteomics first commercialisation deal for PromarkerD 18 Aug 2016 8:42AM $0.220 $0.155 fallen by 29.55%
$26 Appendix 3B 4 Aug 2016 3:52PM $0.240 $0.155 fallen by 35.42%
$26 Appendix 4C - June 2016 Quarterly Report 28 Jul 2016 9:44AM $0.240 $0.155 fallen by 35.42%
$26 Final Director's Interest Notice 30 Jun 2016 11:52AM $0.265 $0.155 fallen by 41.51%
$26 Final Director's Interest Notice 28 Jun 2016 5:16PM $0.250 $0.155 fallen by 38%
$26 Board Changes 28 Jun 2016 5:00PM $0.250 $0.155 fallen by 38%
$26 PromarkerD Development Advances in China 14 Jun 2016 9:25AM $0.215 $0.155 fallen by 27.91%
$26 Proteomics gaining strong traction in Analytical Services 20 May 2016 9:16AM $0.160 $0.155 fallen by 3.13%
$26 Appendix 4C - March 2016 Quarterly Report 26 Apr 2016 9:15AM $0.200 $0.155 fallen by 22.50%
$26 Proteomics to expand operations in Indian Market 14 Apr 2016 11:55AM $0.255 $0.155 fallen by 39.22%

601 - 625 of 686 results

Page 25 of 28

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.